2wpu
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | [[ | + | ==CHAPERONED RUTHENIUM METALLODRUGS THAT RECOGNIZE TELOMERIC DNA== |
+ | <StructureSection load='2wpu' size='340' side='right' caption='[[2wpu]], [[Resolution|resolution]] 1.92Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[2wpu]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Streptomyces_avidinii Streptomyces avidinii]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2WPU OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2WPU FirstGlance]. <br> | ||
+ | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=KYT:(3AS,4S,6AR)-4-(5-((3R,4R)-3,4-DIAMINOPYRROLIDIN-1-YL)-5-OXOPENTYL)TETRAHYDRO-1H-THIENO[3,4-D]IMIDAZOL-2(3H)-ONE-P-CYMENE-CHLORO-RUTHENIUM(III)'>KYT</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br> | ||
+ | <tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1swh|1swh]], [[2bc3|2bc3]], [[1vwq|1vwq]], [[1sre|1sre]], [[1swf|1swf]], [[2rtb|2rtb]], [[1lcw|1lcw]], [[1hxz|1hxz]], [[1swp|1swp]], [[1rxj|1rxj]], [[1swe|1swe]], [[1mm9|1mm9]], [[2rto|2rto]], [[1swa|1swa]], [[2rtr|2rtr]], [[2rtd|2rtd]], [[1stp|1stp]], [[1n43|1n43]], [[2izh|2izh]], [[1sri|1sri]], [[1slf|1slf]], [[1swc|1swc]], [[1vwr|1vwr]], [[1swl|1swl]], [[1ndj|1ndj]], [[1str|1str]], [[1slg|1slg]], [[1vwm|1vwm]], [[1swd|1swd]], [[1swq|1swq]], [[1swu|1swu]], [[1i9h|1i9h]], [[1swj|1swj]], [[2rtj|2rtj]], [[2rtl|2rtl]], [[2iza|2iza]], [[1vwn|1vwn]], [[1vwk|1vwk]], [[1vwg|1vwg]], [[1moy|1moy]], [[1sts|1sts]], [[1hqq|1hqq]], [[1vwi|1vwi]], [[2izg|2izg]], [[1swg|1swg]], [[2izb|2izb]], [[1swk|1swk]], [[2izk|2izk]], [[1luq|1luq]], [[1sws|1sws]], [[1n4j|1n4j]], [[2izd|2izd]], [[1lcv|1lcv]], [[1swt|1swt]], [[1df8|1df8]], [[1vwl|1vwl]], [[1vwb|1vwb]], [[2rtk|2rtk]], [[1srj|1srj]], [[1kl3|1kl3]], [[2rti|2rti]], [[2izf|2izf]], [[1swr|1swr]], [[2rth|2rth]], [[2rtm|2rtm]], [[2izi|2izi]], [[1vwf|1vwf]], [[1vwh|1vwh]], [[1pts|1pts]], [[1mk5|1mk5]], [[1hxl|1hxl]], [[2f01|2f01]], [[1vwd|1vwd]], [[1nc9|1nc9]], [[1sle|1sle]], [[1vwj|1vwj]], [[2ize|2ize]], [[2rtf|2rtf]], [[2rtp|2rtp]], [[1n9y|1n9y]], [[1n9m|1n9m]], [[1hy2|1hy2]], [[1lcz|1lcz]], [[1nqm|1nqm]], [[1vwa|1vwa]], [[2izl|2izl]], [[1kl5|1kl5]], [[2izc|2izc]], [[1mep|1mep]], [[1sld|1sld]], [[1rxh|1rxh]], [[1rsu|1rsu]], [[1vwc|1vwc]], [[1nbx|1nbx]], [[1srh|1srh]], [[2izj|2izj]], [[1rst|1rst]], [[1kff|1kff]], [[1srg|1srg]], [[1vwe|1vwe]], [[2rtg|2rtg]], [[1rxk|1rxk]], [[1kl4|1kl4]], [[1srf|1srf]], [[2rtq|2rtq]], [[2rte|2rte]], [[1swb|1swb]], [[1vwo|1vwo]], [[2rta|2rta]], [[2rtc|2rtc]], [[2rtn|2rtn]], [[1swo|1swo]], [[1swn|1swn]], [[1n7y|1n7y]], [[1vwp|1vwp]]</td></tr> | ||
+ | <tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2wpu FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2wpu OCA], [http://www.rcsb.org/pdb/explore.do?structureId=2wpu RCSB], [http://www.ebi.ac.uk/pdbsum/2wpu PDBsum]</span></td></tr> | ||
+ | <table> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The mode of action of precious metal anticancer metallodrugs is generally believed to involve DNA as a target. However, the poor specificity of such drugs often requires high doses and leads to undesirable side-effects. With the aim of improving the specificity of a ruthenium piano-stool complex towards DNA, we employed a presenter protein strategy based on the biotin-avidin technology. Guided by the X-ray structure of the assembly of streptavidin and a biotinylated piano-stool, we explored the formation of metallodrug-mediated ternary complexes with the presenter protein and DNA. The assemblies bound more strongly to telomere G-quadruplexes than to double-stranded DNA; chemo-genetic modifications (varying the complex or mutating the protein) modulated binding to these targets. We suggest that rational targeting of small molecules by presenter proteins could be exploited to bind metallodrugs to preferred macromolecular targets. | ||
- | + | Chemo-Genetic Optimization of DNA Recognition by Metallodrugs using a Presenter-Protein Strategy.,Zimbron JM, Sardo A, Heinisch T, Wohlschlager T, Gradinaru J, Massa C, Schirmer T, Creus M, Ward TR Chemistry. 2010 Sep 28. PMID:20878805<ref>PMID:20878805</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
==See Also== | ==See Also== | ||
*[[Avidin|Avidin]] | *[[Avidin|Avidin]] | ||
- | + | == References == | |
- | == | + | <references/> |
- | < | + | __TOC__ |
+ | </StructureSection> | ||
[[Category: Streptomyces avidinii]] | [[Category: Streptomyces avidinii]] | ||
[[Category: Creus, M.]] | [[Category: Creus, M.]] |
Revision as of 00:54, 2 October 2014
CHAPERONED RUTHENIUM METALLODRUGS THAT RECOGNIZE TELOMERIC DNA
|